The 2026 MLB trade deadline is a month away, and Steve Cohen suggested to the New York Post on Wednesday that the Mets will be selling because of their shrinking playoff odds.
But unlike most teams that end up selling this time of year, the Mets will not be doing so in the middle of a full-fledged rebuild. They could use prospects, yes, but they will also need pieces who can help them next year, when they intend to contend again.
Given those circumstances, this Mets deadline will be both complicated and pivotal. We reached out to some rival executives to get an idea of which players contending teams will see as assets and what they might give up for them.
Here is a very early take on who is most likely to go and what kind of talent the Mets might be able to get in return.
All of this is speculative and subject to change depending on when the Mets sell: If they start selling now, they will find a market low on supply and middling on demand. If they wait until other teams sort out their fates, their assets will be part of a bigger supply, but demand might also be more drastic, too. In other words, stay tuned.
VERY LIKELY TO GO
LHP Brooks Raley
Raley’s name comes up in almost every conversation about the Mets’ trade deadline. He is an experienced lefty who can handle righties and whose contract is expiring after this season. He is having one of the better seasons of his career, pitching to a 2.32 ERA with 34 strikeouts in 31 innings. The 38-year-old will probably be one of the better relievers available, and certainly one of the better non-closers on the market.
Given that, one could look to a few recent deals to inform a potential return: The optimistic extreme would be the Mets’ deal for Tyler Rogers last season, one in which they sent three prospects, two ranked in their system’s top 15, to the Giants in exchange for the veteran reliever. That might have been a slight overpay, and Rogers consistently ranks among baseball's best in terms of Stuff+ (His 133 is best among all relievers this year, while Raley is tied for 31st).
A more conservative comparison might be the deal the Mets made for Ryan Helsley last year, in which they sent three players to the Cardinals, also including two prospects ranked in their system’s top 15. Both of those deals came closer to the deadline.
LHP A.J. Minter
Minter, like Raley, is an experienced lefty who can also handle righties. Minter, like Raley, will be a free agent after this season. He has not allowed a run in 13 appearances since returning from shoulder surgery this year, has a 3.12 career ERA, and pitched in a World Series-winning bullpen for the Braves in 2021. His 101 Stuff+ does not inspire as much confidence as Raley’s, but his track record and performance should make him appealing to a similar group of suitors. His return seems likely to be less than Raley’s, particularly if teams have concerns about the fact that he is still within a year of major shoulder surgery. But one could spin it this way, too: He has fewer innings on his arm over the last two seasons than just about any proven reliever who will be available, which could make him fresher for October.
Peralta struggled again against the Blue Jays on Wednesday, making it three bad starts in his last five. His 4.81 ERA is the worst of his career as a regular starter by nearly a full run, and he is battling his mechanics in ways that appear to be affecting his stuff and on-field morale.
Still, Peralta is a durable starter in a contract year, and because his issues appear to be the result of some inadvertent changes to his delivery early this season, pitching-savvy teams should have reason to believe they can fix him. He is also a good budget option in a starting pitching market that can often be rather costly: He is owed $8 million total this season, meaning any team trading for him would only inherit approximately $2.5 million prorated salary he is owed after the deadline. That would seemingly make him a good option for everyone from big-market teams looking for help to smaller-market teams hoping to bolster rotations without major investment.
Perhaps, obviously, the Mets will not get back what they gave up for Peralta. And his struggles will not help his value. Still, veteran Yusei Kikuchi was traded with a 4.75 ERA in his walk year two years ago, and that deal netted the Astros three prospects that ranked in the Blue Jays’ top 15 at the time, all of whom have since played in the majors. Track record counts for something.
Even in a worst-case scenario, consider the return the Orioles got last year for veteran Charlie Morton, who was more expensive, a decade older and pitching worse than Peralta when they traded him to the Tigers at last year’s deadline. He netted the Orioles a prospect named Micah Ashman, who struck out Cal Raleigh and Roman Anthony in the WBC this spring and has 50 strikeouts in 30 innings in Double-A this year. Proven starters can return value, even if it is not as much as the Mets gave up to get him.
SP Clay Holmes
Given the state of the Mets' rotation heading into 2027, they should probably consider extending Holmes, who was a stalwart for them earlier this season before breaking his leg on a comebacker in May. But if they are not able to do that, they should trade him, and multiple executives pointed to the deal that the Blue Jays made to acquire Shane Bieber last year as a potential template.
Holmes is not currently healthy. He is throwing his first bullpen since his injury this week, and he will need time to build back up to a starter’s workload from there. As such, he might not be available to audition for teams in time for the Aug. 3 trade deadline. If he is, he might not be able to offer much of a sample.
Bieber was even less of a sure thing when the Jays traded for him last year. He had not pitched in a major league game in more than a year and was due back from Tommy John surgery in the last month of the year. Toronto, needing starting depth, traded a respected pitching prospect for him anyway, planning for his return.
Holmes has pitched well more recently than Bieber had. He is not coming back from an arm injury. He is on an expiring contract that will owe him a bit less than $5 million in prorated salary for August and September, which is affordable for a frontline starter, but could be prohibitive for small-market teams. Still, all of that suggests the Mets should be able to get more than the Guardians got for Bieber – and they got a former second-round pick and a top-five prospect from the Jays system in Kahl Stephen.
Stephen needs elbow surgery that has stalled his rise up prospect rankings, but he was pitching to a 3.44 ERA in 12 Double-A starts before the injury.
IF THE PRICE IS RIGHT
RHP Huascar Brazobán
Multiple executives raised Brazobán’s name as one the Mets could consider moving at this deadline, even though he is not on an expiring contract. The formerly volatile righty is compiling the most consistent season of his career, pitching to a 1.94 ERA with a sub-1.00 WHIP in a variety of bullpen roles.
Unlike the other relievers mentioned here, Brazobán is entering his second year of arbitration and will not be a free agent until after the 2029 season. He is, therefore, a more affordable relief option than many available this time of year, which could appeal to contending teams trying to improve their bullpens on a budget. Because of his success this year and that extended team control, any deal for Brazobán should secure the Mets a legitimate prospect or two. If it doesn’t, they do not need to trade him: After all, the 2027 Mets will need cost-controlled relievers, too.
RP Luke Weaver
Multiple executives speculated about the potential availability of Weaver, who has not allowed a run since April 30. He has been one of the best relievers in baseball this season, walking just nine batters while striking out 39 in 36 innings and is maintaining a career-low 0.806 WHIP. He is also under contract through next season at a reasonable top reliever rate of $11 million for 2027 – a price any mid- or big-market team intending to contend next year would happily pay to lock down a bullpen stalwart before an unpredictable offseason.
But the Mets are a team that intends to contend next year, and keeping the pairing of Weaver and Devin Williams intact would mean not having to start from scratch in the bullpen, at least. Both Cohen and David Stearns have acknowledged the possibility that too much roster turnover, implemented too quickly, might have contributed to the 2026 team’s early struggles.
So Weaver’s status likely depends on more variables than, say, Raley's or Minter's. First, it depends on Cohen and Stearns’ goals for this deadline. If they decide they need to salvage as much as they possibly can from this season and strip the roster for every possible asset, Weaver certainly would bring significant value. But neither the owner nor his president of baseball operations has operated in extremes this year.
More likely, the plan for Weaver will depend on how many teams decide to sell and how many elite relievers are available. If supply is sparse, the potential return might help the Mets more in 2027 than Weaver would.
LONGSHOTS
Cohen told the Post on Wednesday that he does not see the Mets moving either of their high-priced superstars, Lindor or Soto. That should end 95 percent of all speculation about whether Lindor will be traded. He is on this list for one reason: If the Mets decide they need to recalibrate the heart of the roster – whether due to clubhouse dynamics or multiple years of on-field malaise -- the last five-and-a-half years of Lindor’s $341 million contract are still easier to shop than the billions and eons remaining on Soto’s.
Could a team in need of a long-term middle infield solution and a middle-of-the-order bat decide Lindor is better than what will be available to them in the free-agent market? Or that cost certainty on a player of his caliber is an asset heading into the lockout? That does not seem impossible, particularly for a POBO with a history of trading big, veteran contracts for one another like Stearns did with Brandon Nimmo and Marcus Semien.
Still, Lindor is an extremely valuable hitter at his position who has committed himself to New York and proven himself capable of handling ups and downs here. It is not easy to envision the kind of deal that would inspire Cohen to part with him, let alone to shop him while planning to win again in 2027.
SP Sean Manaea
In keeping with the idea that all starting pitchers with any recent history of success qualify as treasured assets this time of year, Manaea is a starting pitcher with some recent history of success. Some team might be willing to bet his revived velocity, 3.53 ERA, and 3.16 Fielding Independent Pitching (FIP) marks since May 22 are representative of the pitcher he will be for the remaining year and a half of his three-year contract – or that they can make him even better.
But given how much he struggled early in the season, and the fact that he still has one-year remaining on a three-year, $75 million deal, he seems likely to appeal to a smaller group of high-payroll teams – unless the Mets want to pay down his contract. Then again, they will also need starters in 2027, not to mention down the stretch in 2026.
Right-handed hitting outfielders are notoriously hard to find, and Taylor is an excellent defender who provides credible at-bats as a fourth outfielder. He is making $3.8 million this year, so even at a prorated price, teams could likely find cheaper options. But the free-agent-to-be is known as a strong defender and could potentially fit a contender needing a veteran on the bench.
COVERS INTEL:
